IMUNON, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 USD | 0.00% |
|
+23.08% | +111.76% |
| Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
| Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Imunon 2023 Virtu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.44
USD
Average target price
12
USD
Spread / Average Target
+733.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +111.76% | 13.54M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IMNN Stock
- News Imunon, Inc.
- Transcript : Imunon, Inc. - Special Call
